Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | DRD4 | P21917 | 1/20 | 0.43 |
| ▸ | TACR1 | P25103 | 1/20 | 0.40 |
| ▸ | AURKA | O14965 | 1/20 | 0.40 |
| ▸ | POLQ | O75417 | 9/20 | 0.39 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | DRD3 | P35462 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | GRM5 | P41594 | 1/20 | 0.38 |
| ▸ | MC4R | P32245 | 1/20 | 0.37 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2258080 | 0.82 | LMNA (0.48) | ALDH1A1KDM4EDRD4DRD3MEN1 | |
| SCHEMBL2257784 | 0.82 | SIGMAR1 (0.48) | DRD2DRD3MEN1KMT2AGRM5 | |
| SCHEMBL2256149 | 0.81 | ALDH1A1 (0.53) | ALDH1A1KDM4ETGFBR1MEN1TSHR | |
| SCHEMBL2258114 | 0.81 | MAPT (0.49) | ALDH1A1KDM4EDRD2DRD3MEN1 | |
| SCHEMBL2258118 | 0.81 | TP53 (0.49) | ALDH1A1KDM4EMEN1TSHRKMT2A | |
| SCHEMBL2259046 | 0.80 | MAPT (0.47) | ALDH1A1KDM4EMEN1TSHRKMT2A | |
| SCHEMBL2258557 | 0.80 | MEN1 (0.48) | ALDH1A1KDM4EMEN1TSHRKMT2A | |
| SCHEMBL2257410 | 0.80 | MEN1 (0.48) | ALDH1A1KDM4EDRD2DRD3MEN1 | |
| SCHEMBL2255578 | 0.80 | GAA (0.56) | ALDH1A1KDM4EDRD2DRD3MEN1 | |
| SCHEMBL2261419 | 0.80 | MEN1 (0.61) | ALDH1A1MEN1TSHRKMT2AGRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2121621-B1 | LXR AND FXR MODULATORS | EXELIXIS PATENT CO LLC (US) | 2014-05-07 | — | — | EP | disclosed |
| US-7998995-B2 | LXR and FXR modulators | EXELIXIS PATENT COMPANY LLC (US) | 2011-08-16 | — | — | US | disclosed |
| US-7998995-B2 | LXR and FXR modulators | EXELIXIS PATENT COMPANY LLC (US) | 2011-08-16 | — | — | US | disclosed |
| US-7998995-B2 | LXR and FXR modulators | EXELIXIS PATENT COMPANY LLC (US) | 2011-08-16 | — | — | US | disclosed |
| US-20100069367-A1 | LXR and FXR Modulators | EXELIXIS, INC. (US) | 2010-03-18 | — | — | US | disclosed |
| US-20100069367-A1 | LXR and FXR Modulators | EXELIXIS, INC. (US) | 2010-03-18 | — | — | US | disclosed |
| US-20100069367-A1 | LXR and FXR Modulators | EXELIXIS, INC. (US) | 2010-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069367-A1 | LXR and FXR Modulators | NR1H3, NR1H2, NR1H4 | ALDH1A1 3692/4885KDM4E 2153/4885DRD4 2249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.